Short Interest in Traws Pharma, Inc. (NASDAQ:TRAW) Increases By 198.4%

Traws Pharma, Inc. (NASDAQ:TRAW) was the recipient of a significant growth in short interest during the month of May. As of May 15th, there was short interest totaling 1,671,345 shares, a growth of 198.4% from the April 30th total of 560,036 shares. Currently, 19.1% of the shares of the company are short sold. Based on an average trading volume of 10,790,912 shares, the short-interest ratio is presently 0.2 days.

Traws Pharma Stock Down 3.9%

Traws Pharma stock traded down $0.06 during trading hours on Friday, reaching $1.46. 376,268 shares of the company’s stock were exchanged, compared to its average volume of 6,455,541. The firm’s 50 day simple moving average is $1.61 and its 200 day simple moving average is $1.80. Traws Pharma has a twelve month low of $1.00 and a twelve month high of $3.27. The firm has a market capitalization of $14.83 million, a PE ratio of -0.86 and a beta of 1.47.

Traws Pharma (NASDAQ:TRAW) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.39. Analysts anticipate that Traws Pharma will post -2.23 EPS for the current year.

Insider Buying and Selling at Traws Pharma

In other Traws Pharma news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the company’s stock in a transaction dated Thursday, April 16th. The stock was bought at an average cost of $1.67 per share, for a total transaction of $998,207.43. Following the completion of the transaction, the insider owned 1,203,250 shares in the company, valued at approximately $2,009,427.50. This represents a 98.71% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 14.00% of the company’s stock.

Hedge Funds Weigh In On Traws Pharma

A number of hedge funds have recently bought and sold shares of TRAW. Two Sigma Investments LP boosted its stake in shares of Traws Pharma by 37.1% in the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after buying an additional 5,955 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Traws Pharma by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after buying an additional 18,213 shares during the last quarter. State Street Corp purchased a new position in shares of Traws Pharma in the 4th quarter worth approximately $29,000. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Traws Pharma by 121.2% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after buying an additional 400,000 shares during the last quarter. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Traws Pharma in the 4th quarter worth about $175,000. 7.95% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have commented on TRAW shares. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Traws Pharma in a research report on Wednesday, May 20th. Wall Street Zen downgraded Traws Pharma to a “strong sell” rating in a research note on Saturday. Finally, Weiss Ratings downgraded Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.00.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.